Cerebrospinal fluid ATP metabolites in multiple sclerosis

Multiple Sclerosis

Volumn 16, Issue 5, 2010, Pages 549-554

  Lazzarino, G ^a   Amorini, A M ^b   Eikelenboom, M J ^c   Killestein, J ^c   Belli, A ^c   Di Pietro, V ^b   Tavazzi, B ^b   Barkhof, F ^c   Polman, C H ^c   Uitdehaag, B M J ^c   Petzold, A ^c,d  

^a UNIVERSITY OF CATANIA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Axonal injury; Disability; Disease subtype; Multiple sclerosis; Neurofilament phosphoforms; Prognosis

Indexed keywords

ADENOSINE TRIPHOSPHATE; INTERFERON; NEUROFILAMENT PROTEIN;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN METABOLISM; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; QUANTITATIVE ANALYSIS;

ADENOSINE TRIPHOSPHATE; ADULT; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS; SEVERITY OF ILLNESS INDEX;

EID: 77952825583     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510364196     Document Type: Article

References (38)

1. Trapp BD, Peterson JP, Ransohoff RM, Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N Eng J Med 1998 ; 338: 278-285.
2. Trapp BD, Stys PK Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009 ; 8: 280-291.
3. Kapoor R., Davies M., Blaker P., Hall S., & Smith K. Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration Ann Neurol, 2003 ; 53: 174-180.
4. Waxman SG Membranes, myelin, and the pathophysiology of multiple sclerosis. N Engl J Med 1982 ; 306: 1529-1533.
5. Waxman SG Nitric oxide and the axonal death cascade. Ann Neurol 2003 ; 53: 150-153.
6. Petzold A. CSF biomarkers for improved prognostic accuracy in acute CNS disease. Neurol Res 2007 ; 29: 691-708.
7. Barkhof F., Calabresi PA, Miller DH, Reingold SC Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009 ; 5: 256-266.
8. Witte ME, Bo L., Rodenburg RJ, et al. Enhanced number and activity of mitochondria in multiple sclerosis lesions. J Pathol 2009 ; 219: 193-204.
9. Mahad DJ, Ziabreva I., Campbell G., et al. Mitochondrial changes within axons in multiple sclerosis. Brain 2009 ; 132: 1161-1174.
10. Su KG, Banker G., Bourdette D., Forte M. Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis. Curr Neurol Neurosci Rep 2009 ; 9: 411-417.
11. Blokhin A., Vyshkina T., Komoly S., Kalman B. Variations in mitochondrial DNA copy numbers in MS brains. J Mol Neurosci 2008 ; 35: 283-287.
12. Almeida A., Heales SJ, Bolanos JP, Medina JM Glutamate neurotoxicity is associated with nitric oxide-mediated mitochondrial dysfunction and glutathione depletion. Brain Res 1998 ; 790: 209-216.
13. Jacobson J., Duchen MR, Hothersall J., Clark JB, Heales SJ Induction of mitochondrial oxidative stress in astrocytes by nitric oxide precedes disruption of energy metabolism. J Neurochem 2005 ; 95: 388-395.
14. Vanlangenakker N., Van den Berghe T., Krysko DV, Festjens N., Vandenabeele P. Molecular mechanisms and pathophysiology of necrotic cell death. Curr Mol Med 2008 ; 8: 207-220.
15. Baud O., Li J., Zhang Y., Neve RL, Volpe JJ, Rosenberg PA Nitric oxide-induced cell death in developing oligodendrocytes is associated with mitochondrial dysfunction and apoptosis-inducing factor translocation. Eur J Neurosci 2004 ; 20: 1713-1726.
16. Lang-Rollin ICJ, Rideout HJ, Noticewala M., Stefanis L. Mechanisms of caspase-independent neuronal death: energy depletion and free radical generation. J Neurosci 2003 ; 23: 11015-11025.
17. Humphrey SM, Holliss DG, Seelye RN Myocardial adenine pool depletion and recovery of mechanical function following ischemia. Am J Physiol 1985 ; 248: H644 - H651.
18. Domanski L., Safranow K., Ostrowski M., et al. Oxypurine and purine nucleoside concentrations in renal vein of allograft are potential markers of energy status of renal tissue. Arch Med Res 2007 ; 38: 240-246.
19. De Jong JW, Keijzer E., Huizer T., Schoutsen B. Ischemic nucleotide breakdown increases during cardiac development due to drop in adenosine anabolism/catabolism ratio. J Mol Cell Cardiol 1990 ; 22: 1065-1070.
20. Humphrey SM, Holliss DG, Cartner LA The influence of inhibitors of the atp degradative pathway on recovery of function and high energy phosphate after transient ischemia in the rat heart. J Mol Cell Cardiol 1986 ; 18 (Suppl 4). 55S - 59S.
21. Amorini AM, Petzold A., Tavazzi B., et al. Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem 2009 ; 42: 1001-1006.
22. Petzold A., Eikelenboom MJ, Keir G., et al. Axonal damage accumulates in the progressive phase of multiple sclerosis: A 3-year follow-up study. J Neurol Neurosurg Psychiatry 2005 ; 76: 206-211.
23. McDonald WI, Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 ; 50: 121-127.
24. Kurtzke JF Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 ; 33: 1444-1452.
25. Kalkers NF, Bergers E., Castelijns JA, et al. Optimizing the association between disability and biological markers in MS. Neurology 2001 ; 57: 1253-1258.
26. Petzold A., Keir G., Green AJE, Giovannoni G., Thompson EJ A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003 ; 278: 179-190.
27. Narayana PA, Doyle TJ, Lai D., Wolinsky JS Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998 ; 43: 56-71.
28. Clark JB N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev Neurosci 1998 ; 20: 271-276.
29. De Stefano N., Filippi M. MR spectroscopy in multiple sclerosis. J Neuroimaging 2007 ; 17 (Suppl 1). 31S - 35S.
30. Regenold WT, Phatak P., Makley MJ, Stone RD, Kling MA Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression. J Neurol Sci 2008 ; 275: 106-112.
31. Smith KJ Conduction properties of central demyelinated and remyelinated axons, and their relation to symptom production in demyelinating disorders. Eye (Lond) 1994 ; 8: 224-237.
32. Davey GP, Canevari L., Clark JB Threshold effects in synaptosomal and nonsynaptic mitochondria from hippocampal CA1 and paramedian neocortex brain regions. J Neurochem 1997 ; 69: 2564-2570.
33. Davey GP, Peuchen S., Clark JB Energy thresholds in brain mitochondria. potential involvement in neurodegeneration. J Biol Chem 1998 ; 273: 12753-12757.
34. Rush AM, Dib-Hajj SD, Liu S., Cummins TR, Black JA, Waxman SG A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc Natl Acad Sci U S A 2006 ; 103: 8245-8250.
35. Craner MJ, Kataoka Y., Lo AC, Black JA, Baker D., Waxman SG Temporal course of upregulation of Na(v)1.8 in Purkinje neurons parallels the progression of clinical deficit in experimental allergic encephalomyelitis. J Neuropathol Exp Neurol 2003 ; 62: 968-975.
36. Black JA, Newcombe J., Trapp BD, Waxman SG Sodium channel expression within chronic multiple sclerosis plaques. J Neuropathol Exp Neurol 2007 ; 66: 828-837.
37. Waxman SG Acquired channelopathies in nerve injury and MS. Neurology 2001 ; 56: 1621-1627.
38. Altmann DR, Jasperse B., Barkhof F., et al. Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology 2009 ; 72: 595-601.